Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Conditions
Glioblastoma, IDH-wildtype · MGMT-Methylated Glioblastoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University Hospital Graz, Graz, Austria
Medizinische Universität Innsbruck, Innsbruck, Austria
Kepler University Hospital, Linz, Austria
University Hospital St. Pölten, Sankt Pölten, Austria
Aarhus University Hospital, Aarhus, Denmark
Haukeland University Hospital, Bergen, Norway
Sorlandet Sykehus, Kristiansand, Norway
Oslo University Hospital, Oslo, Norway
Stavanger University Hospital, Stavanger, Norway
St Olavs Hospital, Trondheim, Norway
Gävle Hospital, Gävle, Sweden
Sahlgrenska University Hospital, Gothenburg, Sweden
Ryhov County Hospital, Jönköping, Sweden
Contact: Study coordinator (PI Michael Strandéus)Kalmar Country Hospital, Kalmar, Sweden
Skåne University Hospital, Lund, Sweden
Örebro University Hospital, Örebro, Sweden
Karolinska Institutet, Stockholm, Sweden
Sundsvall Hospital, Sundsvall, Sweden
Norrlands Universitetssjukhus, Umea, Sweden, Umeå, Sweden
Uppsala University Hospital, Uppsala, Sweden
Study leads
Annika Malmström, MD, PhD
Principal Investigator
University Hospital, Linkoeping